BBa_B1006 1 BBa_B1006 Terminator (artificial, large, %T~>90) 2006-08-30T11:00:00Z 2015-08-31T04:07:21Z modified E. coli thr terminator, replaced all A-T pairs in stem with C-G pairs Released HQ 2013 Artificial terminator, estimated %T~>90% *8bp stem, 6nt loop *Bidirectional, estimated reverse %T~>90% false true _41_ 0 745 41 In stock false Bidirectional, with the reverse estimated to be less effective than the forward. Has a polyA tail of 9 residues. true Haiyao Huang annotation1898430 1 PolyA range1898430 1 32 39 annotation1898428 1 B1006 range1898428 1 1 39 annotation1898431 1 PolyA range1898431 1 1 9 annotation1898429 1 modified thr terminator range1898429 1 10 31 BBa_M39111 1 BBa_M39111 Vector for creation of micro-dystrophin SFV 2012-05-14T11:00:00Z 2015-05-08T01:14:07Z This part came from a combination of a portion of the SFV genome, in addition to the micro-dystrophin genomic sequence and standard promoters and terminator. Released HQ 2013 The general purpose of our part is to help create a modified Semliki Forest Virus that contains micro-dystrophin mRNA in its capsid, which hopefully will be used to deliver said mRNA to muscle cells of muscular dystrophy patients. This DNA vector contains an RNA polymerase promoter, the packaging sequence from SFV (Semliki Forest Virus), the DNA sequence for micro-dystrophin, and an RNA polymerase terminator (Bba_B1006). Once this vector is transcribed into RNA in vitro, the resultant RNA is introduced into a cell in the lab. A separate helper vector (not included in this part) will be introduced into the same cell as well. This other vector will simply contain the genes for the structural proteins of SFV. Once the helper vector is translated to produce the structural capsid proteins, the virus will assemble within the cell, packaging the micro-dystrophin mRNA within the capsid of the virus. The purpose of removing the non-structural genes (other than the necessary packaging sequence) is to remove the replicating and virulent ability of the virus, so that it will not replicate within the body. This virus will then break free of the cell in which it was produced, at which point it can be harvested and injected into patients to treat dystrophin deficiency within muscle cells. true false _1206_ 0 13167 9 Discontinued false We had to make sure only to include the packaging sequences of SFV, so that it would not be able to replicate within the patient's cells. This should also reduce the virulent capabilities of the virus. false Hannah Kempton annotation2175190 1 modified thr terminator range2175190 1 10 31 annotation2175192 1 BBa_B1006 range2175192 1 1 39 annotation2175189 1 PolyA range2175189 1 1 9 annotation2175188 1 B1006 range2175188 1 1 39 annotation2175191 1 PolyA range2175191 1 32 39 BBa_M39111_sequence 1 aaaaaaaaaccccgcccctgacagggcggggtttttttt BBa_B1006_sequence 1 aaaaaaaaaccccgcccctgacagggcggggtttttttt igem2sbol 1 iGEM to SBOL conversion Conversion of the iGEM parts registry to SBOL2.1 James Alastair McLaughlin Chris J. Myers 2017-03-06T15:00:00.000Z